Some Patients Don't Respond to Inflammation Protocols. There's a Reason.
Delta-6 desaturase — the rate-limiting enzyme in essential fatty acid metabolism — is impaired in a significant portion of patients with chronic inflammation. EZtrek® is the only U.S. patented medical food designed to bypass it entirely, delivering the downstream metabolites the body can no longer produce.
You Were Never Taught
to Look Here
Medical training covers inflammation extensively — but almost never addresses the metabolic enzyme that determines whether your patient can actually resolve it. When this enzyme fails, every protocol downstream fails with it.
The Enzyme Shuts Down
Delta-6 desaturase is the rate-limiting step in essential fatty acid metabolism. Aging, genetics, insulin resistance, and chronic illness can impair it — silently blocking your patient's ability to fight inflammation.
Supplements Can't Fix It
No matter how much omega-3, fish oil, or curcumin you give — if this enzyme isn't functioning, your patient physically cannot convert it to the anti-inflammatory eicosanoids they need. The raw materials go in. Nothing useful comes out.
Patients Plateau
The result is treatment-resistant inflammation that erodes patient trust and practitioner confidence — not because of a flawed protocol, but because of a metabolic bottleneck nobody identified.
The Conversion Step That
Determines Everything
The delta-6 desaturase pathway converts essential fatty acids into anti-inflammatory eicosanoids. When this pathway is impaired, inflammation cannot be properly resolved — regardless of treatment intensity, dietary intervention, or supplementation.
This is why some patients never respond. It is not a compliance issue. It is not a dosing issue. It is a conversion issue — and until you address it directly, downstream protocols cannot work.
Skip the Broken Step Entirely
EZtrek® is a patented medical food — not a supplement — formulated to deliver the downstream metabolites your patient's body can't produce on its own. It bypasses the impaired enzyme completely.
Conventional Supplementation
- Requires a functioning D6D enzyme
- Provides raw materials only
- No clinical oversight required
- Available to anyone, anywhere
- Inconsistent results in sick patients
The Pathway Bypass
- Bypasses D6D entirely
- Delivers pre-formed downstream metabolites (GLA)
- FDA medical food classification
- Practitioner-controlled access
- Designed for treatment-resistant cases
How EZtrek® works — three-step bypass
Bypasses the Block
Delivers pre-formed GLA and other downstream metabolites that do not require delta-6 desaturase conversion.
Restores the Missing Link
Provides the exact building blocks for anti-inflammatory eicosanoid production — the compounds your patient's body has been unable to make.
Resolves Where Nothing Else Could
Practitioners report measurable improvements in previously non-responsive cases — COPD, chronic pain, cardiovascular inflammation, and more.
Outcomes Rarely Seen
With Any Intervention
Cardiovascular inflammation is among the most clinically significant applications. The data below reflects physician-reported outcomes in cases where conventional protocols had already been exhausted.
7 months on EZtrek®
Lyme / Mold / inflammatory issues
with EZtrek® alone
"86-year-old patient experienced a significant bilateral orbitofrontal and nasal crushing injury in a fall. Surprisingly had much less nasal injury than expected — no fractured nasal bones or orbital floor fracture. Within 10 days, she demonstrated remarkable resolution of the facial edema and bruising. Her overall recovery was unusually expedited and uncomplicated."
Cancer Center
Results in Previously
Non-Responsive Patients
Real outcomes from practitioners — in cases where conventional approaches had already failed before EZtrek® was added.
"54-yr-old female. Pneumothorax with collapsed lung. CT showed significant scarring. Pulmonologist stated, 'Your case is grim.' Required 24-hour oxygen. After one month on EZtrek®, she no longer requires oxygen and can speak and move about without being winded. Nothing else changed."
"Diagnosed with COPD over 10 years ago, stage 2. Albuterol for 10 years plus Symbicort and Prednisone. When I started EZtrek®, within an hour, I could actually feel my lungs opening. I am no longer using my Albuterol. More energy, walking without being winded."
"54-yr-old female with COPD and Covid-related lung damage. Pneumothorax with collapsed lung. CT showed significant scarring. Required 24-hour oxygen. After one month on EZtrek®, she no longer requires oxygen. Nothing else changed."
"85 years old. Diagnosable diseases: Dementia / Alzheimer's. Completely immobile, bed/wheelchair bound. Rapidly declined since August. Hospice accepted her — 6 months or less to live. [With EZtrek® for 4 months] they will remove her from the program, which is remarkable. The only thing I have done is given her EZtrek®."
"Before his brain injuries, John was a very good writer. Since then, it's been a struggle. He recently wrote 3 separate things to family members, and I was amazed at what he said and how he said it."
"Patient taking EZtrek® for 1 month and her brain fog and mental clarity have greatly improved — a result of decreased inflammation of the brain. Epstein-Barr, hypothyroid, Lyme, post-Covid fatigue. Nothing else changed."
"Elderly woman in early 90's, absence seizure-like activity for many years; communicated intermittently. After 1 month on EZtrek®, she started to speak more spontaneously. Maintained for months. Absence seizure-like behavior has stopped."
"Swelling in her proximal interphalangeal and metacarpophalangeal joints of her hands and wrist reduced by 75% since she has been taking 2 tsp of EZtrek® [morning / evening doses]."
"I injured my back mid-2021. I started using EZtrek® and within 7 days the muscle inflammation in my back subsided to the point that I moved freely without concern."
"52-yr female. Stage 4 breast cancer for 17 years. Mets to bone and liver. Chemo-induced neuropathy plus 3 years. After 3 weeks on EZtrek®: less pain from neuropathy. More energy, feels stronger."
"As a physician and surgeon personally using EZtrek® to facilitate treatment of inflammatory conditions (gout). Since starting EZtrek® I have never had another gout attack."
"92-yr female, 3 fractures of hip. Had been taking EZtrek® for 6 months prior to falling. Projected home using walker: 6-8 weeks. Recovery was unusually expedited."
"Baseline non-contrast CT Agatston Score of 727 on 4/30/2021: Score reduced to 666 on 6/30/2022 [7 months taking EZtrek®]. This translates to an annualized calcified plaque reduction of 14.3% — a result rarely seen with any intervention."
"20-yr hypertensive on Norvasc and Hydrochlorothiazide. BP stabilized at 138/90. When EZtrek® was added, after 3 months BP reduced to 126/75."
"Blood pressure consistently raising until approx. 178/93. Low salt diet stabilized BP at 160/85. Within 30 days of EZtrek®, BP lowered near 126/69, consistently measured."
"86-year-old patient experienced a significant bilateral orbitofrontal and nasal crushing injury in a fall. Surprisingly had much less nasal injury than expected, including no fractured nasal bones. Within 10 days, remarkable resolution of facial edema and bruising. Her facial soft tissues and bones were more resilient — the bones also not brittle."
"I've had the pt. on EZtrek® for 6 months. Since then, she has had no eczema flareups."
"Physician self-patient: suffering from total body eczema, some areas worse. Three-month treatment with EZtrek® — 2 tsp/day first month, 1 daily dose months 2 and 3. My eczema is 90% resolved."
"2 months ago: 2 enlarged axillary lymph nodes, swollen left breast duct, 30% larger left breast. Today: excellent bilaterally equal and normal texture, no lymph node enlargement or breast swelling. Only difference: she has taken EZtrek®."
"3 hs-CRP tests conducted — June: 1.4, mid-September: 1.8, late November: 0.7. The 0.7 value [61% decrease] represents approximately 3.5 weeks of EZtrek® use."
"History of CHF, likely induced from Lyme. hs-CRP went from 1.5 to 1.1. The 1.1 value [27% decrease] represents 4 weeks of EZtrek® use."
"(CHF patient) — Homocysteine decreased from 13 to 9 [31% decrease] after 4 weeks of EZtrek® use."
"72 y/o male, elevated PSA of 6.2 in 04/2021. Mold toxicity. 2 months with EZtrek®: rt posterior lesion shrunk from 0.9x0.7 cm to 0.7x0.6 cm — a 33% decrease in area."
Test It on Your Most
Difficult Case
Before committing to wholesale inventory, evaluate EZtrek® firsthand. The Single-Patient Pilot is a complete 3-month intensive protocol — priced for new practitioners to observe the full clinical course on one of their treatment-resistant patients.
What This Means
for Your Practice
This is not only a clinical tool — it is a practice differentiator. Practitioners implementing this approach see benefits on both sides of their business.
Better Outcomes
Reach the patients who have been stuck — the chronic cases that haven't responded to anything else. When they finally improve, your reputation grows with every referral.
Clear Differentiation
Offer something no one else in your area has — a patented medical food backed by real biochemistry. This is how a serious clinical practice stands apart.
Recurring Revenue
Wholesale pricing with no minimum orders. Patients who experience results stay on it indefinitely — predictable monthly reorders, with full control over your retail margin.
A Revenue Stream That
Earns While You Practice
EZtrek® is a 30-day supply — and once patients experience results, most stay on it indefinitely. That is not a one-time sale. That is a recurring revenue line that compounds as your patient base does.
Wholesale pricing is available exclusively to licensed practitioners — with margins that make this one of the more attractive products in a clinical practice. No revenue share. No platform fees.
30-day supply — reordered every month
Each bottle is a 30-day supply. Patients on maintenance don't stop — they reorder. Predictable, recurring revenue from every patient you put on it.
Designed for long-term use
The goal isn't a 90-day course — it's long-term metabolic support. Practitioners keep patients on EZtrek® indefinitely, which means the revenue compounds the longer your practice uses it.
They can only get it through you
Practitioner-only access means patients return to your practice every 30 days. Not on Amazon. Not in pharmacies. Not at any retail store.
Speak Directly with Prof. Brian Peskin
Have questions about the science, the mechanism, or how to apply EZtrek® in your most challenging cases? Book a complimentary 15-minute consultation directly with the creator of EZtrek® — a rare opportunity reserved exclusively for licensed practitioners.
Prof. Brian Peskin
World-leading researcher in essential fatty acids & metabolic inflammation. MIT-trained scientist, U.S. patent holder, and author. Founder of Peskin Pharmaceuticals®.
Book Your 15-Minute Call
Direct with Prof. Brian Peskin · EZtrek® Creator
From Doctors Who Were Skeptical —
Until Their Patients Responded
This is the first intervention I've had for my most stubborn inflammation cases. Patients who weren't responding to anything are finally seeing improvement.
The mechanism is elegant — bypass the impaired enzyme, deliver what the body needs. Why didn't I think of this before?
I have been taking EZtrek® for one month. Energy increased 30%, mucous has subsided. I am putting my patients, as well as my children, on the product.
I was skeptical at first, but the science made sense. Now it's a staple in my protocols for chronic inflammatory conditions.
Common Questions from Practitioners
Your Patients Are Waiting
for an Answer That Works
Start with the $60 Sample Pack — 3 bottles, shipping included — and evaluate EZtrek® on your most treatment-resistant patient. Then move to the Professional Discount case when you're ready to stock your practice.
Order the Sample Pack — $60